Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma, Inc. Chief Legal Compliance Officer and Corporate Secretary Ray Sumita reported a sale of 1,844 shares of common stock on October 12, 2026, at $28.05 per share. The shares were sold automatically under the issuer’s Company-Wide Policy to satisfy mandatory tax withholding through a sell-to-cover transaction; the sale was not discretionary, and Sumita did not control its timing, price, or share count. The sale was connected with restricted stock unit vesting and settlement. Sumita directly held 116,701 shares after the transaction. No Rule 10b5-1 plan is reported.
Cue Biopharma, Inc. (CUE) VP, Prin. Accounting Officer Michael Vincent Meluzio reported a sale of 1,144 shares of common stock on October 12, 2026, at $28.05 per share, leaving 47,817 shares held directly. Under the issuer's Company-Wide Policy, the shares were sold automatically to satisfy mandatory tax withholding through a sell-to-cover transaction tied to restricted stock unit vesting and settlement. Meluzio did not control the timing, price or number of shares sold. No Rule 10b5-1 plan is reported.
Cue Biopharma, Inc. Chief Executive Officer Shao-Lee Lin reported direct sales of 10,000 common shares at $27.50 per share and 1,087 shares at $28.05 per share on October 12, 2026. The automatic sell-to-cover transactions were made under the issuer’s Company-Wide Policy to satisfy mandatory tax withholding obligations connected with restricted stock unit vesting and settlement; Lin did not control their timing, prices or share counts.
Shao-Lee Lin, identified as an officer and director of Cue Biopharma, Inc., proposes to sell 11,087 common shares on October 12, 2026, at an aggregate market value of $305,490.35. Lin says the proposed sale will cover tax withholding obligations tied to restricted stock unit vesting and settlement and is not discretionary.
Cue Biopharma, Inc. Corporate Secretary Sumita Ray reported a proposed sale of 1,844 common shares, with an aggregate market value of $51,724.20, on October 12, 2026. The shares relate to restricted stock units vesting on October 9, 2026; the sale is intended to cover tax withholding through a “sell to cover” transaction and is described as non-discretionary. Sumita Ray reported selling 8,829 common shares on August 13, 2026, with an aggregate market value of $266,106.06, during the prior three months.
Cue Biopharma, Inc. reported beneficial ownership of 644,916 shares (8.50%) for reporting person Mark E. Strome, Strome Group, Inc.’s sole director, president and chief executive officer. Strome Group and Strome Investment Management, LP each reported 643,242 shares (8.48%); Strome Mezzanine Fund II, L.P. reported 593,242 (7.82%), and Strome Dynasty, LLC reported 50,000 (0.66%). The ownership rows include shared voting and dispositive authority attributed across related entities. Mezzanine II reported warrants exercisable for up to 222,839 underlying shares within 60 days; the warrant ownership limit was adjusted from 5.0% to 8.50%, effective August 15, 2026.
Cue Biopharma, Inc. (CUE) reported positive topline results from a Phase 2 trial of CUE-221 in chronic spontaneous urticaria (CSU), a randomized, double-blind, placebo- and active-controlled study in China enrolling 145 patients with moderate to severe CSU inadequately controlled on H1 antihistamines. Patients received CUE-221 at 4, 2, or 1 mg/kg subcutaneously every 4 weeks, placebo, or omalizumab 300 mg.
The primary endpoint, complete resolution of hives (HSS7=0) at Week 12, was dose-responsive and met at all CUE-221 dose levels, with 54% of patients at 4 mg/kg achieving HSS7=0 versus 11% on placebo. The key secondary endpoint, complete response (UAS7=0) at Week 12, reached statistical significance at 4 mg/kg, where 46% achieved UAS7=0 versus 11% on placebo. Complete hive resolution peaked at Week 22 (69% at 4 mg/kg) and remained 60% at Week 28, 12 weeks after the last dose, compared with 11% for placebo and 24% for omalizumab; a post hoc analysis showed a 36 percentage-point difference versus omalizumab at Week 28. Cue Biopharma reports a favorable safety profile, with no treatment-related serious adverse events, no anaphylaxis, and few injection site reactions, and plans to initiate a Phase 2b/3 trial in CSU and a Phase 2 trial in food allergy, subject to regulatory review.
Cue Biopharma, Inc. (symbol: CUE) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cue Biopharma, Inc. (CUE) reports an amended Form 4 for director Pamela Garzone to correct a prior administrative calculation error in a grant of restricted stock units (RSUs). The original report showed 21,800 shares acquired; the correct amount is 18,900 shares, which is now also the total beneficially owned following the transaction. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to her continued service with the company.
Cue Biopharma, Inc. (CUE) is the subject of a Schedule 13D report by its President, Chief Executive Officer and director, Dr. Shao-Lee Lin, who beneficially owns 467,166 shares of Common Stock, representing 6.2% of the class. This consists of 378,458 shares held directly, 20,471 shares issuable upon settlement of vested RSUs within 60 days, and options exercisable for up to 68,237 shares within 60 days. The percentage is based on 7,405,436 shares outstanding as of August 18, 2026, plus the RSU and option shares counted for beneficial ownership.
Dr. Lin’s equity arises largely from employment compensation, including a fully vested 327,537-share RSU grant in May 2026, a separate 327,537-share RSU grant vesting quarterly over 48 months, and 327,537 performance stock units that vest in three tranches tied to stock price hurdles of $33.00, $38.50, and $44.00 for five consecutive trading days. A trust for her benefit also purchased Pre-Funded Warrants for up to 90,906 shares at an exercise price of $0.001 and Warrants for up to 45,453 shares at $11.00, for an aggregate purchase price of $999,966, but these instruments are subject to a 4.99% Beneficial Ownership Blocker and are not currently exercisable.